Literature DB >> 24574762

Evolving treatment strategies for colorectal cancer: a critical review of current therapeutic options.

Daniel C Damin1, Anderson R Lazzaron1.   

Abstract

Management of rectal cancer has markedly evolved over the last two decades. New technologies of staging have allowed a more precise definition of tumor extension. Refinements in surgical concepts and techniques have resulted in higher rates of sphincter preservation and better functional outcome for patients with this malignancy. Although, preoperative chemoradiotherapy followed by total mesorectal excision has become the standard of care for locally advanced tumors, many controversial matters in management of rectal cancer still need to be defined. These include the feasibility of a non-surgical approach after a favorable response to neoadjuvant therapy, the ideal margins of surgical resection for sphincter preservation and the adequacy of minimally invasive techniques of tumor resection. In this article, after an extensive search in PubMed and Embase databases, we critically review the current strategies and the most debatable matters in treatment of rectal cancer.

Entities:  

Keywords:  Colorectal cancer; Neoadjuvant chemo-radiotherapy; Rectal cancer; Sphincter preservation; Staging; Surgery

Mesh:

Year:  2014        PMID: 24574762      PMCID: PMC3921541          DOI: 10.3748/wjg.v20.i4.877

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  88 in total

Review 1.  Robotic surgery: a current perspective.

Authors:  Anthony R Lanfranco; Andres E Castellanos; Jaydev P Desai; William C Meyers
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

2.  Is the 1-cm Rule of Distal Bowel Resection Margin in Rectal Cancer Based on Clinical Evidence? A Systematic Review.

Authors:  Krzysztof Bujko; Andrzej Rutkowski; George J Chang; Wojciech Michalski; Ewa Chmielik; Jerzy Kusnierz
Journal:  Indian J Surg Oncol       Date:  2012-06

3.  Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial.

Authors:  L Påhlman; B Glimelius
Journal:  Ann Surg       Date:  1990-02       Impact factor: 12.969

4.  Surgeon-related factors and outcome in rectal cancer.

Authors:  G A Porter; C L Soskolne; W W Yakimets; S C Newman
Journal:  Ann Surg       Date:  1998-02       Impact factor: 12.969

5.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

6.  Routine use of transrectal ultrasound in rectal carcinoma: results of a prospective multicenter study.

Authors:  F Marusch; A Koch; U Schmidt; R Zippel; R Kuhn; S Wolff; M Pross; A Wierth; I Gastinger; H Lippert
Journal:  Endoscopy       Date:  2002-05       Impact factor: 10.093

7.  Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer.

Authors:  N Scott; P Jackson; T al-Jaberi; M F Dixon; P Quirke; P J Finan
Journal:  Br J Surg       Date:  1995-08       Impact factor: 6.939

8.  Robotic versus laparoscopic coloanal anastomosis with or without intersphincteric resection for rectal cancer.

Authors:  Se Jin Baek; Sami Al-Asari; Duck Hyoun Jeong; Hyuk Hur; Byung Soh Min; Seung Hyuk Baik; Nam Kyu Kim
Journal:  Surg Endosc       Date:  2013-05-25       Impact factor: 4.584

9.  Surgeon specialty is associated with outcome in rectal cancer treatment.

Authors:  Thomas E Read; Robert J Myerson; James W Fleshman; Robert D Fry; Elisa H Birnbaum; Bruce J Walz; Ira J Kodner
Journal:  Dis Colon Rectum       Date:  2002-07       Impact factor: 4.585

10.  Transrectal ultrasound and computed tomography in preoperative staging of lower rectal adenocarcinoma.

Authors:  S Goldman; H Arvidsson; U Norming; U Lagerstedt; I Magnusson; J Frisell
Journal:  Gastrointest Radiol       Date:  1991
View more
  14 in total

Review 1.  Colorectal resection via natural orifice specimen extraction versus conventional laparoscopic extraction: a meta-analysis with meta-regression.

Authors:  Y H Chin; G M Decruz; C H Ng; H Q M Tan; F Lim; F J Foo; C H Tai; C S Chong
Journal:  Tech Coloproctol       Date:  2020-08-26       Impact factor: 3.781

Review 2.  Local excision by transanal endoscopic surgery.

Authors:  Luis J García-Flórez; Jorge L Otero-Díez
Journal:  World J Gastroenterol       Date:  2015-08-21       Impact factor: 5.742

Review 3.  Narrative review of theoretical considerations regarding HITHOC between past and future.

Authors:  Tamas F Molnar; Andras Drozgyik
Journal:  Ann Transl Med       Date:  2021-06

4.  Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy.

Authors:  Hui Zhu; Xuejing Yang; Jiali Li; Yanjie Ren; Tianyu Zhang; Chunze Zhang; Jintai Zhang; Jing Li; Yan Pang
Journal:  Biomed Res Int       Date:  2014-07-17       Impact factor: 3.411

Review 5.  A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.

Authors:  Yi Li; Ji Wang; Xiaowei Ma; Li Tan; Yanli Yan; Chaofan Xue; Beina Hui; Rui Liu; Hailin Ma; Juan Ren
Journal:  Int J Biol Sci       Date:  2016-07-17       Impact factor: 6.580

6.  Drug resistance and combating drug resistance in cancer.

Authors:  Xuan Wang; Haiyun Zhang; Xiaozhuo Chen
Journal:  Cancer Drug Resist       Date:  2019-06-19

7.  Extracellular vesicle-mediated phenotype switching in malignant and non-malignant colon cells.

Authors:  Hillary E Mulvey; Audrey Chang; Jason Adler; Michael Del Tatto; Kimberly Perez; Peter J Quesenberry; Devasis Chatterjee
Journal:  BMC Cancer       Date:  2015-08-01       Impact factor: 4.430

Review 8.  Genetic instability in the tumor microenvironment: a new look at an old neighbor.

Authors:  Antonio Palumbo; Nathalia de Oliveira Meireles Da Costa; Martin Hernan Bonamino; Luis Felipe Ribeiro Pinto; Luiz Eurico Nasciutti
Journal:  Mol Cancer       Date:  2015-07-31       Impact factor: 27.401

Review 9.  Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs.

Authors:  Abhineet Uppal; Mark K Ferguson; Mitchell C Posner; Samuel Hellman; Nikolai N Khodarev; Ralph R Weichselbaum
Journal:  Clin Exp Metastasis       Date:  2014-06-27       Impact factor: 5.150

10.  A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options.

Authors:  Florian Eisner; Martin Pichler; Steffen Goletz; Herbert Stoeger; Hellmut Samonigg
Journal:  J Clin Pathol       Date:  2015-09-18       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.